Condition
Severe and inadequately controlled asthma
Total Trials
2
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Bgf Mdi 32014496 Μg
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
100%
2 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
2Total
Phase 3 (2)
Trial Status
Completed2
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (2)
Research Network
Common Treatments
- Bgf Mdi 32014496 Μg2
- Bgf Mdi 32028896 Μg2
- Bff Pmdi 3209 Μg2
- Bff Mdi 32096 Μg2
Active Sponsors
- AstraZeneca2
- Astrazeneca AB2
Top Investigators
Johns Hopkins University
Related Conditions
- Asthma2